{"id":61519,"date":"2026-03-27T12:23:03","date_gmt":"2026-03-27T04:23:03","guid":{"rendered":"https:\/\/flcube.com\/?p=61519"},"modified":"2026-03-27T12:23:04","modified_gmt":"2026-03-27T04:23:04","slug":"joincare-pharmas-jkn2404-wins-nmpa-approval-for-asthma-trial-next-gen-inhaled-corticosteroid-targets-improved-safety-profile","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61519","title":{"rendered":"Joincare Pharma’s JKN2404 Wins NMPA Approval for Asthma Trial \u2013 Next-Gen Inhaled Corticosteroid Targets Improved Safety Profile"},"content":{"rendered":"\n

Joincare Pharmaceutical Group Industry Co., Ltd.<\/strong> (SHA: 600380<\/a>) announced that JKN2404 inhalation suspension<\/strong>, a Category 1 innovative chemical drug<\/strong>, received National Medical Products Administration (NMPA) approval<\/strong> to initiate clinical studies in bronchial asthma<\/strong>. The next-generation, locally acting, highly selective small-molecule inhaled corticosteroid (ICS)<\/strong> targets the glucocorticoid receptor (GR)<\/strong> with an enhanced safety window<\/strong>, aiming to reduce systemic adverse reactions<\/strong> associated with traditional ICS therapy, including HPA axis suppression and pediatric growth retardation<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Type<\/strong><\/td>Clinical trial authorization (IND)<\/td><\/tr>
Product<\/strong><\/td>JKN2404 inhalation suspension<\/td><\/tr>
Developer<\/strong><\/td>Joincare Pharmaceutical Group (SHA: 600380)<\/td><\/tr>
Drug Class<\/strong><\/td>Category 1 innovative chemical drug<\/td><\/tr>
Indication<\/strong><\/td>Bronchial asthma<\/td><\/tr>
Mechanism<\/strong><\/td>Next-generation inhaled corticosteroid (ICS) \u2013 glucocorticoid receptor (GR) selective agonist<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Differentiation<\/h2>\n\n\n\n
Attribute<\/th>JKN2404 Specification<\/th>Traditional ICS Comparison<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Highly selective GR agonist<\/strong> \u2013 regulates inflammation-related gene transcription, inhibits inflammatory factors, modulates immune cell proliferation<\/td>Broader GR activity \u2192 systemic exposure<\/td><\/tr>
Route<\/strong><\/td>Local inhalation<\/strong> \u2013 direct lung delivery<\/td>Same route, but less selective<\/td><\/tr>
Safety Window<\/strong><\/td>Higher therapeutic index<\/strong> \u2013 potent anti-inflammatory effect at lower systemic exposure<\/td>Narrower window \u2192 dose-limited by side effects<\/td><\/tr>
Systemic Side Effects<\/strong><\/td>Reduced risk<\/strong> of HPA axis suppression, growth retardation in children, bone density loss<\/td>Established risks<\/strong> with long-term high-dose use<\/td><\/tr>
Target Population<\/strong><\/td>Pediatric and adult asthma<\/strong> \u2013 particularly patients requiring chronic high-dose ICS<\/strong><\/td>All asthma severities, but safety concerns limit dosing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Market Opportunity<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China Asthma Market<\/strong><\/td>~45 million diagnosed patients<\/strong>; RMB 20+ billion<\/strong> annual drug market; ICS backbone of therapy for 80%+ of patients<\/strong><\/td><\/tr>
ICS Safety Unmet Need<\/strong><\/td>Pediatric growth concerns<\/strong> and adrenal suppression<\/strong> drive dose limitation<\/strong> and patient non-adherence<\/strong> \u2013 JKN2404 addresses core barrier<\/td><\/tr>
Next-Gen ICS Trend<\/strong><\/td>Industry shift toward dissociated GR agonists<\/strong> (separating transactivation from transrepression) \u2013 JKN2404 positions as China-first<\/strong> in this class<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Fluticasone furoate (GSK)<\/strong>, mometasone (Merck)<\/strong> dominate; JKN2404 seeks differentiation via safety<\/strong> rather than efficacy superiority<\/td><\/tr>
Development Pathway<\/strong><\/td>Phase I\/II 2026\u20132027<\/strong>; pediatric studies critical differentiator<\/strong> given safety profile; potential accelerated review<\/strong> for pediatric indication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n